S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The 3-Stock Retirement Blueprint (Ad)
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
NATO chief rejects Russia’s “illegal and illegitimate” annexation of 4 parts of Ukraine
NASDAQ:SLNO

Soleno Therapeutics - SLNO Stock Forecast, Price & News

$1.67
+0.04 (+2.45%)
(As of 09/30/2022 05:36 PM ET)
Add
Compare
Today's Range
$1.60
$1.72
50-Day Range
$1.63
$28.80
52-Week Range
$1.60
$13.78
Volume
36,465 shs
Average Volume
70,273 shs
Market Capitalization
$13.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Soleno Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.43mentions of Soleno Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.05) to ($2.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

423rd out of 1,093 stocks

Electromedical Equipment Industry

5th out of 23 stocks

SLNO stock logo

About Soleno Therapeutics (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Stock News Headlines

Soleno Therapeutics Inc
Why Soleno Therapeutics Shares Are Surging Today
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLNO Company Calendar

Last Earnings
8/10/2022
Today
10/01/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLNO
Employees
17
Year Founded
N/A

Profitability

Net Income
$-30,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.34 per share

Miscellaneous

Free Float
5,771,000
Market Cap
$13.54 million
Optionable
Not Optionable
Beta
0.29

Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 52)
    Pres, CEO, COO & Director
    Comp: $618.7k
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 58)
    Chief Financial Officer
    Comp: $392k
  • Ms. Kristen Yen M.S. (Age 53)
    VP of Clinical Operations
    Comp: $317.19k
  • Ms. Patricia C. Hirano (Age 56)
    VP of Regulatory Affairs
    Comp: $343.35k
  • Mr. Anthony Wondka (Age 60)
    Sr. VP & GM
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., MBA, Sr. VP of Drug Devel.













SLNO Stock - Frequently Asked Questions

How have SLNO shares performed in 2022?

Soleno Therapeutics' stock was trading at $6.15 at the beginning of 2022. Since then, SLNO shares have decreased by 72.8% and is now trading at $1.67.
View the best growth stocks for 2022 here
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Wednesday, August, 10th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.15.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics shares reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $1.67.

How much money does Soleno Therapeutics make?

Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $13.54 million. The company earns $-30,910,000.00 in net income (profit) each year or ($4.0480) on an earnings per share basis.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383.

This page (NASDAQ:SLNO) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.